Thus, sacubitril (SAC), which is a NEP inhibitor (NEP-i), is combined with an ARB (valsartan: VAL) to serve as an AT-II receptor and NEP inhibitor (ANRI) for the treatment of patients with heart failure with reduced ejection fraction [23]. The gene discussed is MME; the disease is heart failure.